. 2014 Dec 11;3(2):101–112. doi: 10.1007/s40120-014-0023-8

Table 1.

Demographics and clinical characteristics of the extension study’s ITT population, recorded at baseline of the randomized, controlled trial

Parameter	Tafamidis–tafamidis (n = 38)	Placebo–tafamidis (n = 33)
Median age, years (range)	36.5 (25 to 74)	34.0 (23 to 71)
Female, n (%)	21 (55)	18 (54)
Caucasian, n (%)	37 (97)	33 (100)
Median duration of TTR-FAP symptoms, months (range)	17.5 (3 to 268)	18.0 (2 to 133)
Mean height, m (SD)	1.66 (0.1)	1.67 (0.1)
Mean weight, kg (SD)	65.1 (12.4)	64.4 (14.4)
Mean weight, kg (SD)	66.2 (11.9)^a	63.3 (14.1)^a
Mean serum albumin, g/l (SD)	43.9 (3.5)	44.2 (4.2)
Mean serum albumin, g/l (SD)	44.7 (3.4)^a	43.1 (4.0)^a
Mean BMI, kg/m² (SD)	23.6 (3.6)	23.1 (5.2)
Mean BMI, kg/m² (SD)	23.9 (3.0)^a	22.7 (5.2)^a
Mean mBMI, kg/m² g/l (SD)	1,031.6 (166.5)	1,020.2 (244.3)
Mean mBMI, kg/m² g/l (SD)	1,068.4 (142.4)^a	990.1 (265.0)^a
NIS-LL (range 0–88)
Mean (SD)	6.8 (10.0)	11.6 (14.5)
Median (range)	4.0 (0 to 49)	6.0 (2 to 57)
TQOL, median (range)	14 (−1 to 110)	17 (0 to 107)
TQOL, median (range)	11 (−1 to 97)^a	28 (−1 to 96)^a

BMI body mass index, ITT intent-to-treat, NIS-LL Neuropathy Impairment Score-Lower Limbs, SD standard deviation, TQOL Norfolk Quality of Life-Diabetic Neuropathy total quality of life, TTR-FAP transthyretin familial amyloid polyneuropathy

^aAt baseline of the open-label extension study